XLO
HEALTHCAREXilio Therapeutics Inc
$7.90+0.19 (+2.46%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving XLO Today?
No stock-specific AI insight has been generated for XLO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.47$16.52
$7.90
Fundamentals
Market Cap$47M
P/E Ratio—
EPS$-4.19
Dividend Yield—
Dividend / Share—
ROE-1.3%
Profit Margin-0.8%
Debt / Equity—
Trading
Volume20K
Avg Volume (10D)—
Shares Outstanding6.0M
XLO News
21 articles- Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 7, 2026
- Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2Yahoo Finance·Apr 17, 2026
- Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of DirectorsYahoo Finance·Apr 16, 2026
- Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 3, 2026
- Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?Yahoo Finance·Apr 1, 2026
- Cancer Stocks to Buy as Innovation Reshapes Global Oncology MarketYahoo Finance·Mar 26, 2026
- Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 23, 2026
- Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual MeetingYahoo Finance·Mar 17, 2026
- Xilio Therapeutics Announces 1-for-14 Reverse Stock SplitYahoo Finance·Mar 12, 2026
- Xilio Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceYahoo Finance·Mar 2, 2026
- Xilio Therapeutics Announces Pricing of Underwritten OfferingYahoo Finance·Feb 12, 2026
- Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate UpdatesYahoo Finance·Jan 8, 2026
- Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial ResultsYahoo Finance·Nov 13, 2025
- BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue EstimatesYahoo Finance·Nov 12, 2025
- Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual MeetingYahoo Finance·Nov 7, 2025
- Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual MeetingYahoo Finance·Nov 7, 2025
- Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual MeetingYahoo Finance·Oct 30, 2025
- Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual MeetingYahoo Finance·Oct 3, 2025
- Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with GileadYahoo Finance·Sep 9, 2025
- Xilio Therapeutics Second Quarter 2025 Earnings: US$0.16 loss per share (vs US$0.32 loss in 2Q 2024)Yahoo Finance·Aug 16, 2025
- Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue EstimatesYahoo Finance·Aug 14, 2025
All 21 articles loaded
Price Data
Open$7.70
Previous Close$7.71
Day High$8.05
Day Low$7.70
52 Week High$16.52
52 Week Low$6.47
52-Week Range
$6.47$16.52
$7.90
Fundamentals
Market Cap$47M
P/E Ratio—
EPS$-4.19
Dividend Yield—
Dividend / Share—
ROE-1.3%
Profit Margin-0.8%
Debt / Equity—
Trading
Volume20K
Avg Volume (10D)—
Shares Outstanding6.0M
About Xilio Therapeutics Inc
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune systems of cancer patients. The company is headquartered in Waltham, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—